Evaluation of a Patient-Centred, Multidisciplinary Opioid Tapering Program for Individuals With Chronic Non-Cancer Pain on Long Term Opioid Therapy
NCT04902547 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 26
Last updated 2026-05-06
Summary
Chronic pain management is complex, with healthcare providers historically relying on prescribing opioid medications such as morphine. Although opioids may partially improve pain, there are risks associated with them as well, including pain worsening, side effects, addiction and overdose. It is now understood that the management of chronic pain is more effective when multiple healthcare team members work together and incorporate multiple strategies instead of focusing solely on medications. An example of an effective, non-drug strategy for pain is a service offered by clinical psychologists called "Acceptance and Commitment Therapy" - or ACT - which empowers individuals, to implement alternative ways of thinking about and reacting to pain and its effect on their lives.
Canada has responded to the opioid overdose crisis with new guidelines that encourage physicians and those suffering from chronic pain to aim for lower opioid doses whenever possible, a process often referred to as "tapering." Unsurprisingly, tapering opioids is often difficult for patients to consider, primarily due to misconceptions that it will cause more harm than good.
This project aims to address these misconceptions by developing and offering an all-day educational workshop for patients, co-presented by a healthcare team (clinical psychologists, pharmacists and physicians), to provide in-depth information on opioid related risks and misconceptions, as well as a large component focusing on ACT training. Investigators then want to see if these sessions change individual attitudes towards opioid tapering and if it improves willingness and ability to successfully reduce opioid doses to a safer level.
Conditions
- Opioid Use
- Opioids; Harmful Use
- Hyperalgesia
- Pain, Chronic
Interventions
- BEHAVIORAL
-
Patient Education Workshop (PEWs)
The comprehensive workshops will include a combination of didactic and interactive content on general pain and opioid education (1 hour workshop session to be co-presented by Drs Ryan Amadeo and Dana Turcotte) along with significant psychological content (co-presented by Drs Brigitte Sabourin and Gregg Tkachuk) making up the remainder of the day-long workshop. Content presented in PEWs will include opioid-related risks, identifying personal motivation for (or barriers to) tapering, goal setting, pain self-management, sleep hygiene and comprehensive focus on ACT and rethinking pain. During the interprofessionally co-facilitated sessions, participants will be provided with workbooks that will contain session specific content as well as take-home activities and information for their own personal use.
- PROCEDURE
-
Multidisciplinary Tapering Program
The MTP will begin with a Baseline Tapering Visit and will include the same baseline health and well-being questionnaires, a medication review, relevant pain history, relevant opioid use history, discussion re: patient-specific tapering and functional goals, taper start date, and determination if a different opioid formulation will be required for the taper. A detailed taper plan will be prepared and reviewed by the study clinician(s) and provided to the patient. In general, tapers will begin with a 10% reduction of dose every 2 weeks until ⅓ of the original dose is met, or until taper goal has been met. If further tapering is planned once the patient reaches ⅓ of their original dose, the taper will be reduced to half the volume and rate noted above in order to improve tapering success. Tapering plans and approaches may be changed (slowed, increased, halted etc.) based on follow up.
Sponsors & Collaborators
-
Winnipeg Regional Health Authority
collaborator OTHER -
University of Manitoba
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-05-01
- Primary Completion
- 2024-01-05
- Completion
- 2026-04-05
Countries
- Canada
Study Locations
More Related Trials
-
Efficacy and Safety of Ultra-low Dose Methadone as Adjuvant Analgesic in Cancer Patients With Pain
NCT02687347 ·Status: UNKNOWN ·Phase: PHASE3
-
Quantitative Sensory Testing in Chronic Pain Patients Undergoing Opioid Treatment and Opioid Tapering
NCT03375216 ·Status: COMPLETED ·Phase: NA
-
Effect of Early Pain Management at Triage on Opioid Consumption
NCT03243006 ·Status: COMPLETED ·Phase: NA
-
Reduced Opioid Analgesic Requirements Via Improved Endogenous Opioid Function
NCT02469077 ·Status: COMPLETED ·Phase: NA
-
Cessation of Long-term Opioid Therapy in Chronic Pain Patients
NCT02132221 ·Status: TERMINATED ·Phase: NA
-
24-hour Oral Morphine Equivalent Based Opioid Prescribing After Surgery
NCT04043143 ·Status: COMPLETED ·Phase: NA
-
Manage My Pain at Chronic Pain Clinics
NCT04762329 ·Status: COMPLETED ·Phase: NA
-
Investigation of Analgesic and Anti-hyperalgesic Effect of Opioids in Experimental Pain
NCT00647127 ·Status: COMPLETED ·Phase: PHASE3
-
Optimal Management of Pain in Hospitalized Patients - Opioid Tolerant Populations.
NCT02470728 ·Status: TERMINATED ·Phase: NA
-
Analgesic Tolerance to Repeated Doses of Subcutaneous Morphine
NCT00256347 ·Status: COMPLETED ·Phase: NA
-
Evaluation of an Opioid Decrease Strategy in Chronic
NCT04424459 ·Status: COMPLETED
-
Comparison of Standard Opioid Prescription Versus Prescription Guided by Pharmacogenetic Analysis in Patients With Non-cancerous Chronic Pain.
NCT03498014 ·Status: WITHDRAWN ·Phase: NA
-
Individualized Pharmaceutical-care for Inpatients With Cancer Pain
NCT03455023 ·Status: UNKNOWN ·Phase: NA
-
Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.
NCT05905146 ·Status: RECRUITING ·Phase: NA
-
Identification of Predictive Markers of the Effects of Opioid Therapy in Patients With Chronic Pain.
NCT03701672 ·Status: UNKNOWN
-
Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain
NCT00225797 ·Status: COMPLETED ·Phase: PHASE3
-
Prospective Study About Clinical and Pharmacogenetic Safety of Opioid Use for Chronic Pain
NCT00916890 ·Status: SUSPENDED ·Phase: PHASE4
-
Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain
NCT01946555 ·Status: COMPLETED
-
Evaluation of Stepped Care for Chronic Pain in Iraq/Afghanistan Veterans (ESCAPE)
NCT00386243 ·Status: COMPLETED ·Phase: NA
-
Prescribing Opioid Pain Relievers in the Emergency Department: Understanding and Optimizing the Encounter
NCT02299024 ·Status: COMPLETED ·Phase: NA
-
Variation in Opioid Prescribing and Use for Acute Pain in Diverse Populations
NCT04509115 ·Status: COMPLETED
-
An Evaluation of the Effect of Community-based Pharmacist Intervention on Patients With Chronic Pain
NCT03087331 ·Status: COMPLETED ·Phase: NA
-
Discontinuation vs Continuation of Long-term Opioid Therapy in Suboptimal and Optimal Responders With Chronic Pain
NCT02741076 ·Status: TERMINATED ·Phase: PHASE4
-
Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain
NCT05674240 ·Status: COMPLETED
-
A Non-interventional, Observational Study for Quality of Life (Overall Health Assessment) in Patients With Chronic Severe Pain During Targinact® Treatment
NCT01710917 ·Status: UNKNOWN